The guidance does not include tests that have clear and relevant recommendations in other guidelines, e.g. Dopamine active transporter (DAT) scanning is covered in NICE guidance.Novel biomarkers not yet used in the clinical routine are not considered, e.g. Tau PET, blood-based biomarkers.Throughout the guideline, the focus is mainly older adult dementia, and investigating young or rapid onset dementia is not covered. The gene discussed is MAPT; the disease is dementia.